加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$1.23
−US$0.07 · -5.38%
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
前收盘价
US$1.23
−US$0.07 · -5.38%
盘中时间采用ET。市场数据可能有所延迟。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日内区间
当前US$1.23
52周区间
当前US$1.23
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
28
偏贵
情绪
43
多空交织
风险
51
风险偏高
动量
30
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日内区间
当前US$1.23
52周区间
当前US$1.23
营业利润
净利润
| 项目（CAD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 6.23万 CAD |
| 销货成本 | — | — | 18.74万 CAD | 16.22万 CAD | 17.43万 CAD |
| 毛利 | — | — | −18.74万 CAD | −16.22万 CAD | −11.2万 CAD |
| 研究与开发 | 1401.85万 CAD | 1401.21万 CAD | 1073.22万 CAD | 1398.83万 CAD | 859.42万 CAD |
| 销售、一般及管理费用 | 2019.59万 CAD | 2589.14万 CAD | 1155.36万 CAD | 1634.29万 CAD | 2186.22万 CAD |
| 营业费用 | 3431.63万 CAD | 4027.67万 CAD | 2228.58万 CAD | 3033.13万 CAD | 3045.64万 CAD |
| 利息收入 | 72.64万 CAD | 119.33万 CAD | 203.85万 CAD | 123.76万 CAD | 10.6万 CAD |
| 折旧和摊销 | 10.2万 CAD | 37.31万 CAD | 24.84万 CAD | 21.99万 CAD | 22.04万 CAD |
| 营业利润 | −3431.63万 CAD | −4027.67万 CAD | −2247.32万 CAD | −3049.35万 CAD | −3056.84万 CAD |
| 净利润 | −3381.89万 CAD | −3667.73万 CAD | −2122.28万 CAD | −2281.75万 CAD | −2501.32万 CAD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.00
上涨空间 550.41%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
